Last reviewed · How we verify
NCT00721656
A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes
Phase 2 trial testing Placebo in Dry Eye Syndromes in 80 participants. Completed.
Quick facts
| Lead sponsor | Kissei Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Sites | 5 locations across Japan |
Drugs / interventions tested
- Placebo
- KLS-0611 — full drug profile →
Conditions studied
- Dry Eye Syndromes — all drugs for Dry Eye Syndromes →
Sponsor
Kissei Pharmaceutical Co., Ltd. — full company profile →
Who can join
20 and older, any sex, with Dry Eye Syndromes. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Corneal-conjunctival staining
Time frame: 4 weeks
Sponsor's own description
To evaluate the efficacy and safety of KLS-0611 compared to placebo in patients with dry eye syndromes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00721656
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Eye Syndromes
Currently open trials in the same condition.
- NCT07412860 — Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hy · NA · recruiting
- NCT06913504 — Comparison Of Blue Light Filter Feature and Blue Blocking Lenses in Digital Device Users With Dry Eye Patients · NA · active not recruiting
- NCT06913465 — The Impact of Hypothyroidism on Tear Production and Dry Eye Symptoms: Implications for Optometric Care · active not recruiting
- NCT06831253 — Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome · NA · recruiting
- NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
Other Kissei Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06757257 — Special Drug Use-results Survey for Long-term Use (Fostamatinib) · recruiting
- NCT05831670 — An Early Phase 2 Clinical Study of KSP-0243 · Phase 2 · completed
- NCT05445167 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain · Phase 3 · completed
- NCT05440383 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia · Phase 3 · completed
- NCT06758271 — Special Drug Use-results Survey for Long-term Use（Avacopan） · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00721656 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kissei Pharmaceutical Co., Ltd.
- Last refreshed: 16 March 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00721656.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing